Health check packages

• Includes the prostate cancer genetic risk test AntePC.
• Recommended for men aged 40-70.
• Analyses 121 genetic variants.

Prostate cancer is the most common malignant tumour among men, accounting for 25% of all cancer cases. Only 39% of cases are detected at an early stage. However, early-stage prostate cancer is successfully treatable.

The five-year survival rate for patients with early-detected prostate cancer is almost 100%. However, only about 30% of patients with advanced prostate cancer live for five years or more.

The risk of prostate cancer increases quite rapidly as a man gets older. It is very important to know that prostate cancer usually progresses without symptoms in its early stages, which is why it is important to take preventive measures. International professional organisations recommend prostate cancer prevention based on personalised risk levels.

• Includes the colorectal cancer genetic risk test AnteCRC.
• Recommended for men aged 40-75.
• Analyses 91 genetic variants.

Colorectal cancer is a common disease that affects women and men equally. It develops slowly and may be asymptomatic in its early stages. Colorectal cancer is the most common cause of cancer deaths among people under 60.

In 50% of cases, colorectal cancer is advanced at the time of diagnosis, which means the prognosis is poor. Advanced stage colorectal cancer is often difficult to treat, which is why prevention is vital.

However, 55% of colorectal cancer cases are preventable. Colorectal cancer can be prevented through a personalised approach and early detection.

• Includes the skin melanoma genetic risk test AnteMEL.
• Recommended for men aged 18-70.
• Analyses 28 genetic variants.

Melanoma is the most aggressive form of skin cancer and its incidence is increasing rapidly. Melanoma is the second most common cancer in younger people (15-29 years old).

Melanoma often develops in areas that have been repeatedly sunburned, but it can also occur in protected areas of the skin. Regular skin checks and monitoring of changes are key. If melanoma is detected at an early stage, the chance of recovery is over 90%.

• The service is based on polygenic risk score technology and up-to-date research.
• The polygenic risk score takes into account the combined effect of hundreds or thousands of gene variants that influence the risk of developing a specific type of cancer.
• The genetic tests are developed by the Estonian health technology company Antegenes. The tests comply with the regulations for clinical use. All tests are CE-marked in vitro medical devices (IVDs) registered with the Health Board.

• To perform the test, you must provide a sample from the cheek mucosa with a cotton swab, from which your DNA is extracted. This is a painless and simple procedure.
• The results will arrive within six weeks and will remain available in your Health Portal.
• From the report you will find out your risk assessments and precise instructions for further preventive check-ups and health behaviour.
• The service also includes a Confido Digital Clinic consultation for interpreting your test results and receiving further recommendations. Use the code provided by the nurse when booking your appointment.